| Literature DB >> 35720273 |
Peng Chen1, Cheng Zhong1, Shengxi Jin1, Yiyin Zhang1, Yirun Li1, Qiming Xia1, Jiaxi Cheng1, Xiaoxiao Fan1,2, Hui Lin1,2.
Abstract
Lipids are involved in both energy metabolism and signaling transduction. Abnormal lipid metabolism in T cells is associated with the differentiation, longevity and activity of T cells, which has received increasing concern since its firstly reported in 1985. To evaluate the trends of lipid metabolism in T cells and map knowledge structure, we employed bibliometric analysis. A total of 286 related publications obtained from the Web of Science Core Collection published between 1985 and 2022 were analyzed using indicators of publication and citation metrics, countries, institutes, authors, cited references and key words. The present research status, the global trends and the future development directions in lipid metabolism and T cells were visualized and discussed. In summary, this study provides a comprehensive display on the field of lipid metabolism in T cells, which will help researchers explore lipid metabolism in T cells more effectively and intuitively.Entities:
Keywords: Bibliometric; Citespace; T lymphocytes; VOSviewer; lipid metabolism
Mesh:
Year: 2022 PMID: 35720273 PMCID: PMC9204382 DOI: 10.3389/fimmu.2022.884030
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1Flowchart of the screening process.
Figure 2Overall distribution of publication outputs on lipid metabolism in T cells (A) Global annual output trends; (B) Global annual citation.
Figure 3Analysis of countries/regions. (A) Geographical distribution of global output; (B) Radar map of the top 10 productive countries; (C) Radar map of TGCS of the top 10 productive countries; (D) Visual cluster analysis of cooperation among countries.
The top 11 productive countries concerning lipid metabolism in T cells.
| Rank | Country | Counts | TLCS1 | TGCS2 |
|---|---|---|---|---|
| 1 | USA | 123 (42.4%) | 387 | 12227 |
| 2 | China | 42 (14.5%) | 0 | 512 |
| 3 | UK | 37 (12.8%) | 33 | 2082 |
| 4 | Germany | 28 (9.7%) | 50 | 1415 |
| 5 | Italy | 19 (6.6%) | 18 | 411 |
| 6 | France | 17 (5.9%) | 25 | 826 |
| 7 | Japan | 17 (5.9%) | 0 | 313 |
| 8 | Switzerland | 14 (4.8%) | 17 | 811 |
| 9 | Canada | 11 (3.8%) | 59 | 1646 |
| 10 | Austria | 10 (3.4%) | 11 | 298 |
| 11 | Sweden | 10 (3.4%) | 4 | 158 |
1 TLCS, total local citation score.
2 TGCS, total global citation score.
The top 12 productive institutions concerning lipid metabolism in T cells.
| Rank | Institution | Country | Counts | TLCS1 | TGCS2 |
|---|---|---|---|---|---|
| 1 | Harvard Medical School | USA | 10 (3.4%) | 13 | 670 |
| 2 | St Jude Children’s Research Hospital | USA | 10 (3.4%) | 44 | 826 |
| 3 | Karolinska Inst | Sweden | 9 (3.1%) | 4 | 148 |
| 4 | Harvard University | USA | 8 (2.8%) | 5 | 1473 |
| 5 | Stanford University | USA | 8 (2.8%) | 22 | 1308 |
| 6 | National Cancer Institute | USA | 6 (2.1%) | 11 | 494 |
| 7 | French National Centre for Scientific Research | French | 6 (2.1%) | 8 | 558 |
| 8 | Duke University | USA | 5 (1.7%) | 68 | 1590 |
| 9 | University Oxford | UK | 5 (1.7%) | 16 | 278 |
| 10 | University Penn | USA | 5 (1.7%) | 41 | 1440 |
| 11 | Vanderbilt University | USA | 5 (1.7%) | 4 | 162 |
| 12 | Yale University | USA | 5 (1.7%) | 17 | 492 |
1 TLCS, total local citation score.
2 TGCS, total global citation score.
Figure 4Analysis of institutions and authors. (A) Radar map of the top 12 productive institutions; (B) Visual cluster analysis of cooperation among institutions. (C) The top authors' production over time.
The top 19 productive authors concerning lipid metabolism in T cells.
| Rank | Author | Counts | TLCS1 | TGCS2 |
|---|---|---|---|---|
| 1 | Chi H | 10 | 44 | 826 |
| 2 | Chapman NM | 6 | 5 | 81 |
| 3 | Zhang J | 6 | 3 | 52 |
| 4 | Calder PC | 5 | 0 | 279 |
| 5 | Curi R | 5 | 4 | 94 |
| 6 | Pearce EL | 5 | 44 | 1751 |
| 7 | Zeng H | 5 | 39 | 736 |
| 8 | Bensinger SJ | 4 | 76 | 765 |
| 9 | Berod L | 4 | 19 | 303 |
| 10 | Coquet JM | 4 | 4 | 95 |
| 11 | Getz GS | 4 | 4 | 292 |
| 12 | Parks JS | 4 | 38 | 553 |
| 13 | Rathmell JC | 4 | 67 | 1471 |
| 14 | Reardon CA | 4 | 4 | 292 |
| 15 | Tibbitt CA | 4 | 4 | 95 |
| 16 | Vogel P | 4 | 42 | 705 |
| 17 | Wei J | 4 | 5 | 96 |
| 18 | WICK G | 4 | 5 | 45 |
| 19 | Xu QB | 4 | 5 | 59 |
1 TLCS, total local citation score.
2 TGCS, total global citation score.
The top 10 core journals publishing lipid metabolism in T cells.
| Rank | Journal | Counts | TLCS1 | TGCS2 |
|---|---|---|---|---|
| 1 | Frontiers in Immunology | 19 (6.6%) | 0 | 428 |
| 2 | Journal of Immunology | 10 (3.4%) | 88 | 2197 |
| 3 | Nature | 10 (3.4%) | 93 | 3137 |
| 4 | International Journal of Molecular Sciences | 9 (3.1%) | 0 | 34 |
| 5 | Immunity | 7 (2.4%) | 24 | 1031 |
| 6 | Cell Reports | 6 (2.1%) | 9 | 160 |
| 7 | Nature Immunology | 6 (2.1%) | 41 | 609 |
| 8 | Proc Natl Acad Sci U S A | 6 (2.1%) | 35 | 564 |
| 9 | European Journal of Immunology | 5 (1.7%) | 19 | 269 |
| 10 | Immunology | 5(1.7%) | 5 | 147 |
1 TLCS, total local citation score.
2 TGCS, total global citation score.
The top 10 cited references among the 290 publications.
| Rank | First Author | Year | Journal | DOI |
|---|---|---|---|---|
| 1 | Michalek RD ( | 2011 | Journal of Immunology | 10.4049/jimmunol.1003613 |
| 2 | Pearce EL ( | 2009 | Nature | 10.1038/nature08097 |
| 3 | Daynes RA ( | 2002 | Nature Review Immunology | 10.1038/nri912 |
| 4 | Patsoukis N ( | 2015 | Nature Communications | 10.1038/ncomms7692 |
| 5 | Zeng H ( | 2013 | Nature | 10.1038/nature12297 |
| 6 | Daynes RA ( | 2002 | Cell | 10.1016/j.cell.2008.04.052 |
| 7 | Patsoukis N ( | 2015 | Immunity | 10.1016/j.immuni.2014.06.005 |
| 8 | Daynes RA ( | 2002 | Journal of Immunology | 10.4049/jimmunol.164.3.1364 |
| 9 | Patsoukis N ( | 2015 | Nature | 10.1038/35009119 |
| 10 | Ma C ( | 2016 | Nature | 10.1038/nature16969 |
The top 10 co-cited publications in lipid metabolism in T cells.
| Rank | First Author | Year | Journal | DOI |
|---|---|---|---|---|
| 1 | Michalek RD ( | 2011 | Journal of Immunology | 10.4049/jimmunol.1003613 |
| 2 | Berod L ( | 2014 | Nature Medicine | 10.1038/nm.3704 |
| 3 | Pearce EL ( | 2009 | Nature | 10.1038/nature08097 |
| 4 | Kidani Y ( | 2013 | Nature Immunology | 10.1038/ni.2570 |
| 5 | O’Sullivan D ( | 2014 | Immunity | 10.1016/j.immuni.2014.06.005 |
| 6 | Shi LZ ( | 2011 | Journal of experimental medicine | 10.1084/jem.20110278 |
| 7 | Wang RN ( | 2011 | Immunity | 10.1016/j.immuni.2011.09.021 |
| 8 | Bensinger SJ ( | 2008 | Cell | 10.1016/j.cell.2008.04.052 |
| 9 | van der Windt GJW ( | 2012 | Immunity | 10.1016/j.immuni.2011.12.007 |
| 10 | Zeng H ( | 2013 | Nature | 10.1038/nature12297 |
Figure 5Analysis of cited and co-cited references. (A) Cluster analysis of co-cited references; (B) Timeline distribution of the top seven clusters; (C) Top 10 references with the most strongest citation bursts.
Figure 6Analysis of Keywords. (A) Co-network of keywords; (B) Cluster analysis of keywords; (C) Timeline distribution of the top 15 clusters; (D) Top 10 keywords with the most strongest bursts.
The effect of part metabolites generated in lipid metabolism on T cells.
| Metabolites | Generation Pathway | Key Enzymes | Effect on T cells |
|---|---|---|---|
| FPP1/GGPP2 | Metabolites in CBP | HMGCR3 | Treg ↑ ( |
| Th1 ↑ ( | |||
| Desmosterol | Precursor of cholesterol | HMGCR3 | Th17 ↑ ( |
| 25-hydroxylase | Derivative of cholesterol | CYP25A14 | Th1 ↓ ( |
| 27-hydroxylase | Derivative of cholesterol | CYP27A15 | Th17 ↑ ( |
| CD8+ T ↓ ( | |||
| sphingosine-1-phosphate | Hydrolyzate of phospholipids | ASM6 | Th1 ↓, Th17 ↓ ( |
| Th2 number ↑, activity ↓ ( | |||
| Treg ↑ ( | |||
| CD8+ T ↓ ( | |||
| Prostaglandin E2 | Prostaglandin | COX7, mPGES18 | Th1 ↑, Th17 ↑ ( |
| Treg ↑ ( | |||
| CD8+ T ↑ ( | |||
| Cardiolipin | Glycerophospholipids | GPAM9, PTPMT110 | CD8+ T ↑ ( |
| Platelet activating factor | Glycerophospholipids | GPAM9 | Th17 ↑ ( |
| Long-chain fatty acids | Fatty acid | ACC111, SCD112 | Th1 ↑, Th17 ↑ ( |
| Short-chain fatty acids | Fatty acid | ACC111, SCD112 | Treg ↑ ( |
1FPP, farnesyl pyrophosphate; 2GGPP, geranylgeranyl pyrophosphate; 3HMGCR, HMG-CoA reductase; 4CYP25A1, cytochrome P450 family 25 subfamily A member 1; 5CYP27A1, cytochrome P450 family 27 subfamily A member 1; 6ASM, acid sphingomyelinase; 7COX, cytochrome c oxidase; 8mPGES1, prostaglandin E synthase; 9GPAM, glycerol-3-phosphate acyltransferase, mitochondrial; 10PTPMT1, protein tyrosine phosphatase mitochondrial 1; 11ACC1, acetyl-CoA carboxylase 1; 12SCD1, stearoyl-Coenzyme A desaturase 1. 13↑, increased; 14↓, decreased.
Figure 7The process of lipid metabolism in T cells. The citrate is exported from mitochondria to cytosol by mitochondrial citrate carriers to generate acetyl-CoA and. Acetyl-CoA is the substrate for the biosynthesis of fatty acid synthesis (FAS), cholesterol (CBP), phospholipids and other active lipids. For CBP, HMG-CoA reductase (HMGCR) is the rate-limiting enzyme mediating the synthesis of acetyl-CoA to farnesyl pyrophosphate (FPP), and statins are specific chemicals inhibiting HMGCR. Squalene monooxygenase (SE) is the rate-limiting enzyme mediating the synthesis from squalene to cholesterol, and naftifine, terbinafine, NB-598 are specific chemicals targeting SE. After cellular distribution, excessive cholesterol is disposed of either through exporting outsides the cells or storing as cholesterol esters via cholesterol acyltransferase (ACAT) enzymes, and CI-1011, CI-976, CP-113, CP-818 and K604 are inhibitors of ACAT1. For FAS, Acetyl-CoA is firstly converted into malonyl-COA by acetyl-CoA carboxylase 1 (ACC1), and NDI-010976 and PF-05221304 repress ACC1. Malonyl-COA is further used to synthesize fatty acid through the regulation of FASN ans SCD1. TVB2640 and FT4101 specific target FASN, and specific Aramchol targets stearoyl-Coenzyme A desaturase 1 (SCD1). Fatty acid is synthesized to phospholipids which can hydrolyze to sphingosine-1-phosphate (S1P) through acid sphingomyelinase (ASM), and Amitriptyline suppresses ASM. and it can participate fatty acid oxidation (FAO) after turning into Acyl-COA. Besides, fatty acid can also participate in fatty acid oxidation after entering into mitochondria, which is mediated by CTP1A, and etomoxir is a chemical targeting carnitine palmitoyltransferase 1A (CPT1A).⊣: inhibition.
The effect of part drugs targeting key enzymes in lipid metabolism on T cells.
| Chemicals | Targeted enzymes | Effect on T cells |
|---|---|---|
| Statin | HMGCR1 | Th1 ↑ ( |
| Th1 ↓ ( | ||
| Th17 ↓ ( | ||
| Th2 ↑ ( | ||
| Treg ↑ ( | ||
| Treg ↓ ( | ||
| CD8+ T ↑ ( | ||
| Avasimibe | ACAT12 | CD8+ T ↑ ( |
| PF-05221304 | ACC13 | Th1 ↓, Th17 ↓ ( |
| Soraphen A | ACC13 | Th17 ↓ ( |
| Treg ↑ ( | ||
| Amitriptyline | ASM4 | Th2 number ↑, activity ↓ ( |
| Treg ↑ ( | ||
| CD8+ T ↓ ( | ||
| Etomoxir | CPT1A5 | Th17 ↓ ( |
| Treg ↑ ( | ||
|
| ||
| CD8+ T ↓ ( |
1HMGCR, HMG-CoA reductase; 4ACAT1, acetyl-CoA acetyltransferase 1; 3ACC1, acetyl-CoA carboxylase 1; 4ASM, acid sphingomyelinase; 5CPT1A, carnitine palmitoyltransferase 1A; 6TM, memory T cells; 7↑, increased; 8↓, decreased.